Ticker

Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) was the recipient of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 53,039 shares, a drop of 52.0% from the January 29th total of 110,410 shares. Based on an average daily volume of 28,117 shares,

SOLANA BEACH, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the fiscal year…

Artelo Biosciences (NASDAQ: ARTL) held its 2025 annual meeting of stockholders virtually on Jan. 30, 2026, led by President and Chief Executive Officer Gregory Gorgas. The meeting included the company's formal stockholder votes on director elections, executive compensation, and auditor ratification, followed by a question-and-answer session that ended without any submitted questions. Meeting attendance and procedures

Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 48,967 shares, a decline of 73.7% from the December 15th total of 185,968 shares. Based on an average daily volume of 76,858 shares,

Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a large growth in short interest in December. As of December 15th, there was short interest totaling 185,968 shares, a growth of 82.6% from the November 30th total of 101,848 shares. Based on an average daily volume of 2,280,304 shares, the days-to-cover ratio is presently 0.1